

## 14960

## EphB4 (D1C7N) Rabbit mAb



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

## For Research Use Only. Not for Use in Diagnostic Procedures.

| Applications:           | Reactivity: | Sensitivity:  | MW (kDa): | Source/Isotype: | UniProt ID: | Entrez-Gene Id: |
|-------------------------|-------------|---|-----------|-----------------|-------------|-----------------|
| W, IP, IHC-P, IF-IC     | H           | Endogenous  | 135       | Rabbit IgG      | #P54760     | 2050            |
| Product Usage           |             | Application   |           |                 |             | Dilution        |
| Information             |             | Western Blotting  |           |                 |             | 1:1000          |
|                         |             | Immunoprecipitation   |           |                 |             | 1:50            |
|                         |             | Immunohistochemistry (Paraffin)   |           |                 |             | 1:500           |
|                         |             | Immunofluorescence (Immunocytochemistry)  |           |                 |             | 1:800           |
| Storage                 |             | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.  For a carrier free (BSA and azide free) version of this product see product #78650. |           |                 |             |                 |
| Specificity/Sensitivity |             | EphB4 (D1C7N) Rabbit mAb recognizes endogenous levels of total EphB4 protein.   |           |                 |             |                 |
| Source / Purific        | cation      | Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human EphB4 protein.   |           |                 |             |                 |
| Background              |             | The Eph receptors are the largest known family of receptor tyrosine kinases (RTKs). They can be divided into two groups based on sequence similarity and on their preference for a subset of ligands: EphA  |           |                 |             |                 |

The Eph receptors are the largest known family of receptor tyrosine kinases (RTKs). They can be divided into two groups based on sequence similarity and on their preference for a subset of ligands: EphA receptors bind to a glycosylphosphatidylinositol-anchored ephrin A ligand; EphB receptors bind to ephrin B proteins that have a transmembrane and cytoplasmic domain (1,2). Research studies have shown that Eph receptors and ligands may be involved in many diseases including cancer (3). Both ephrin A and B ligands have dual functions. As RTK ligands, ephrins stimulate the kinase activity of Eph receptors and activate signaling pathways in receptor-expressing cells. The ephrin extracellular domain is sufficient for this function as long as it is clustered (4). The second function of ephrins has been described as "reverse signaling", whereby the cytoplasmic domain becomes tyrosine phosphorylated, allowing interactions with other proteins that may activate signaling pathways in the ligand-expressing cells (5). Various stimuli can induce tyrosine phosphorylation of ephrin B, including binding to EphB receptors, activation of Src kinase, and stimulation by PDGF and FGF (6). Tyr324 and Tyr327 have been identified as major phosphorylation sites of ephrin B1 *in vivo* (7).

The ephrin receptor B4 (EphB4) is normally expressed on venous endothelial cells, while arterial endothelial cells express its ligand, EphrinB2. Together, EphB4 and EphrinB2 play an important roll in vasculature development and maintenance (8). Research studies show that various cancers, including breast, colorectal, esophageal, and pancreatic cancers, express EphB4 (9-12). However, as EphB4 has been shown to have both tumor suppressive and promoting properties, its role in tumorigenesis and tumor progression remains uncertain (13).

## **Background References**

- 1. Wilkinson, D.G. (2000) Int Rev Cytol 196, 177-244.
- 2. Klein, R. (2001) Curr Opin Cell Biol 13, 196-203.
- 3. Dodelet, V.C. and Pasquale, E.B. (2000) Oncogene 19, 5614-9.
- 4. Holder, N. and Klein, R. (1999) Development 126, 2033-44.
- 5. Brückner, K. et al. (1997) Science 275, 1640-3.
- 6. Palmer, A. et al. (2002) *Mol Cell* 9, 725-37.
- 7. Kalo, M.S. et al. (2001) *J Biol Chem* 276, 38940-8.
- 8. Wang, H.U. et al. (1998) Cell 93, 741-53.
- 9. Kumar, S.R. et al. (2006) Am J Pathol 169, 279-93.
- 10. Davalos, V. et al. (2006) *Cancer Res* 66, 8943-8.
- 11. Hasina, R. et al. (2013) *Cancer Res* 73, 184-94.
- 12. Li, M. and Zhao, Z. (2013) Mol Biol Rep 40, 1735-41.
- 13. Noren, N.K. and Pasquale, E.B. (2007) Cancer Res 67, 3994-7.

Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X

TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key W: Western Blotting IP: Immunoprecipitation IHC-P: Immunohistochemistry (Paraffin) IF-IC:

Immunofluorescence (Immunocytochemistry)

Cross-Reactivity Key H: Human

**Trademarks and Patents** Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

SignalStain is a registered trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for

more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.